Page 7 - Prostate Cancer Session
P. 7
TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel
in metastatic castration-resistant prostate cancer
(mCRPC) progressing after docetaxel—Overall
survival after median follow-up of 3 years (ANZUP
1603). Abstract 5000. Hofman M et al.
June 5, 2022
